congresses-banner

The content contained is subject

PublicationView

Poster
Other/Multi
ASCO 2024 | May 31 - June 4, 2024
Other/Multi-Tumor
A phase 1/2, first-in-human study of DS-3939a in patients with advanced solid tumors: A new DXd ADC targeting TA-MUC1
Noboru Yamamoto
Poster
Dato-DXd, T-DXd, Valemetostat
ASCO 2024 | May 31 - June 4, 2024
Gastric Cancer Lung Cancer Other/Multi-Tumor
A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody-drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors
Jacob Sands
Oral
T-DXd
ASCO 2024 | May 31 - June 4, 2024
Breast Cancer
A randomized study comparing electronic patient-reported outcomes monitoring with routine follow-up during trastuzumab deruxtecan treatment for inoperable or metastatic breast cancer patients: PRO-DUCE study
Yuichiro Kikawa
Poster
Dato-DXd
ASCO 2024 | May 31 - June 4, 2024
Other/Multi-Tumor
Analysis of drug-related interstitial lung disease (ILD) in patients treated with datopotamab deruxtecan (Dato-DXd)
Jacob Sands
Poster
Dato-DXd
ASCO 2024 | May 31 - June 4, 2024
Lung Cancer
Datopotamab deruxtecan (Dato-DXd) in Chinese patients with advanced or metastatic non-small cell lung cancer (NSCLC): Results from the phase 1/2 TROPION-PanTumor02 study
Yuping Sun
Poster
Dato-DXd
ASCO 2024 | May 31 - June 4, 2024
Lung Cancer
Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab with or without platinum chemotherapy as first-line therapy for advanced non-small cell lung cancer (NSCLC); subgroup analysis from TROPION-Lung02
Benjamin Levy
Oral
Dato-DXd
ASCO 2024 | May 31 - June 4, 2024
Breast Cancer
Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer: Patient-reported outcomes (PROs) from the TROPION-Breast01 study
Sonia Pernas
Oral
T-DXd
ASCO 2024 | May 31 - June 4, 2024
Breast Cancer
DESTINY-Breast07: Dose-expansion analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC
Fabrice André
Poster
HER3-DXd
ASCO 2024 | May 31 - June 4, 2024
Gastric Cancer Tumor-agnostic
HERTHENA-PanTumor01: A global, multicohort, phase 2 trial of HER3-DXd in relapsed/refractory metastatic solid tumors
Aarti Bhatia
Oral
Dato-DXd
ASCO 2024 | May 31 - June 4, 2024
Lung Cancer
ICARUS-LUNG01: A phase 2 study of Dato-DXd in patients with previously treated advanced NSCLC, with sequential tissue biopsies and biomarkers analysis to predict treatment outcome
David Planchard
Pages: 1  2  3  

footer